<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802266</url>
  </required_header>
  <id_info>
    <org_study_id>Chest 010</org_study_id>
    <nct_id>NCT03802266</nct_id>
  </id_info>
  <brief_title>Electromagnetic Navigation Versus CT Guided TTNA in the Diagnosis of Early Peripheral Lung Cancer</brief_title>
  <official_title>Electromagnetic Navigation Guided Versus CT-guided Transthoracic Needle Aspiration (TTNA) in the Diagnosis of Early Peripheral Lung Cancer, a Randomized Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Electromagnetic navigation guided with CT-guided
      transthoracic needle aspiration (TTNA) in the diagnosis of pulmonary peripheral nodule.

      Primary endpoints：Diagnostic rate Secondary endpoints：operating time、adverse events Study
      design: Multicenter、randomized、open lebel
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic rate</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operating time</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Electromagnetic Navigation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electromagnetic Navigation Guided Transthoracic Needle Aspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CT-guided Transthoracic Needle Aspiration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electromagnetic Navigation guided transthoracic needle aspiration</intervention_name>
    <description>Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule</description>
    <arm_group_label>Electromagnetic Navigation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CT-guided Transthoracic Needle Aspiration</intervention_name>
    <description>Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule</description>
    <arm_group_label>CT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with 0.8-3 cm, high-risk pulmonary peripheral nodules that need biopsy for
             pathological diagnosis;

          2. Patients who are older than 18 year-old;

          3. Patients voluntarily join the study and give written informed consent for the study.

        Exclusion Criteria:

          1. Chest CT scan shows that the pulmonary nodule is pure ground glass opacity.

          2. Large blood vessels or important structures on the puncture path of peripheral lung
             tumors；

          3. Severe cardiopulmonary dysfunction and other indications that can't receive
             bronchoscopy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Zhong, Phd，MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Zhong, Phd，MD</last_name>
    <phone>13818200560</phone>
    <email>eddiedong8@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Zhong, MD,PhD</last_name>
      <phone>86-21-22200000</phone>
      <phone_ext>3902</phone_ext>
      <email>eddiedong8@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shuhui Cao, MD</last_name>
      <phone>86-21-22200000</phone>
      <phone_ext>3909</phone_ext>
      <email>caosh1994@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhong</investigator_full_name>
    <investigator_title>Professor Hua Zhong</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

